Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT02064569
An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene
An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene.
Type: Interventional
Status of the trial: Completed
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 2016-10-13
- Closing Date: 2021-12-12
Criteria
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Neuro-Ophthalmology Rare Diseases (WG2)
This ERN is supported by:
